In May 2023, C4T and Betta Pharmaceuticals entered into a strategic collaboration to develop CFT8919 in China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, C4T is eligible for up to $357 million in potential milestones plus royalties on net sales.
Interested in partnering with us to leverage our MonoDAC℠ or BiDAC℠ research and development capabilities to bring degrader-based medicines to patients?
Email Us To CollaborateYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.
You are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.
